

AZTherapies

Media Contact:

Jennifer LaVin
207-360-0473
jlavin@aztherapies.com

Investor Contact:

Courtney Turiano
212-698-8687
courtney.turiano@sternir.com

AZTherapies to Present at the 25th Annual BIO-EUROPE® International Partnering Conference

BOSTON, Mass., November 4, 2019 – [AZTherapies, Inc.](#), a biopharmaceutical company developing therapeutics to extend brain health, today announced that its Director of Business Development, Parid Sava, Ph.D., will be presenting at [BIO-EUROPE](#)'s 25th Annual International Partnering Conference, taking place from November 11 to 13, 2019 in Hamburg, Germany. The presentation will highlight AZTherapies' lead Phase 3 clinical candidate ALZT-OP1 for the treatment of early Alzheimer's disease and its pipeline of candidates targeting neuroinflammation to treat neurodegenerative diseases.

When: Monday, November 11, 2019 at 4:00 pm

Where: Level 1, Hall B1, Room 6

About BIO-EUROPE

Now celebrating its 25th year, BIO-EUROPE is Europe's largest life science partnering conference. Bringing together international decision makers from the biotechnology, pharmaceutical, and financial sectors, the conference offers networking opportunities, workshop and panel participation, high-profile exhibitions, and prearranged one-to-one meetings. BIO-EUROPE is produced by [EBD Group](#), a leading partnering firm for the global biotechnology industry, with the support of the [Biotechnology Innovation Organization](#) (BIO).

About AZTherapies

AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer's disease is fully enrolled and expected to complete in late 2020. Following our lead program, we are advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company headquartered in Boston, Massachusetts. To learn more, please visit www.aztherapies.com.

###